(WorldFrontNews Editorial):- Sheridan, Wyoming Aug 27, 2026 (Issuewire.com) – A proposed $44 million class action settlement has been reached in In re Chantix (Varenicline) Marketing, Sales Practices & Products Liability Litigation (No. II), Case Nos. 22-MD-3050 (KPF) and 22-MC-3050, pending in the United States District Court for the Southern District of New York. The settlement resolves claims concerning Pfizer Inc.’s manufacture and sale of the smoking-cessation drug Chantix.
According to the court-approved settlement notice, plaintiffs alleged that Pfizer failed to comply with current Good Manufacturing Practices, which they claimed resulted in Chantix becoming contaminated with a nitrosamine. Plaintiffs also alleged that Pfizer misrepresented its adherence to current Good Manufacturing Practices in connection with the manufacture of Chantix.
The litigation asserted claims including violations of state consumer-protection laws, unjust enrichment, negligent misrepresentation and other theories. The court previously limited the claims that could proceed, including certain claims based on allegations concerning Pfizer’s representations about its manufacturing practices. Pfizer denies wrongdoing and denies violating any law. The court has not decided which side is correct.
The parties agreed to settle the case rather than continue through litigation and trial. According to the settlement notice, the agreement allows both sides to avoid the uncertainties and expenses associated with continued litigation while providing compensation to qualifying settlement class members if the settlement receives final approval.
Who May Be Eligible
The Settlement Class generally includes individual consumers and third-party payors who paid any amount of money for retail purchases of Chantix in the United States or its territories from September 29, 2015 through September 17, 2021.
Certain parties are excluded, including Pfizer and specified affiliated individuals and entities, government agencies or governmental actors, and parties that previously excluded themselves from the applicable class.
Settlement Benefits
Pfizer has agreed to establish a $44 million Settlement Fund. Payments to settlement class members, settlement administration and notice expenses, court-approved attorneys’ fees and litigation expenses, and any approved service awards will be paid from the fund.
For individual consumers, up to 20% of the Available Settlement Fund will be allocated to approved consumer claims. Each qualifying consumer’s payment will be calculated on a pro rata basis according to the amount the consumer paid for Chantix, and no consumer payment will exceed the amount that individual paid for the drug.
After the consumer allocation, the remaining funds will generally be distributed to qualifying third-party payors on a pro rata basis according to their qualifying and documented payments.
Because payments depend on the number and value of valid claims submitted, the settlement does not provide a fixed individual payout amount.
Documentation Requirements for Consumers
Individual consumers are not required to submit purchase documentation with their initial claim. However, the Settlement Administrator may later request supporting proof.
Examples of acceptable documentation include:
- An insurance explanation of benefits showing payment for Chantix
- Pharmacy records showing purchases of Chantix
- Records showing prescriptions written for Chantix
Consumers must report the number of Chantix prescriptions they purchased and the amount they paid out of pocket, and must certify that the information provided is accurate. Claims may be audited, and the Settlement Administrator may request additional documentation.
Claim Deadline
The deadline to submit a claim is September 14, 2026. Online claims must be submitted by the applicable deadline, while mailed claim forms must be postmarked no later than September 14, 2026.
The deadline to request exclusion from the settlement or object to the proposed settlement is also September 14, 2026.
The Court has scheduled a Final Approval Hearing for October 13, 2026 at 3:00 p.m. before U.S. District Judge Katherine Polk Failla in the Southern District of New York. The hearing date may change, and settlement class members should review the official settlement materials for updates.
Sparrow, a platform that tracks class action and settlement deadlines, has published information about the Chantix settlement to help consumers review publicly available details concerning eligibility, filing deadlines and settlement benefits. Sparrow is not the Settlement Administrator, Class Counsel or legal counsel in this matter. Individuals should rely on the official settlement website and court-approved documents for complete terms and instructions.
The Settlement Administrator for the matter is A.B. Data, Ltd. Settlement inquiries may be directed to:
Chantix Settlement
c/o A.B. Data, Ltd.
P.O. Box 173137
Milwaukee, WI 53217
Phone: 1-877-354-3912
Court-appointed Class Counsel includes:
Ruben Honik and David J. Stanoch
Honik LLC
Charles E. Schaffer
Levin Sedran & Berman LLP
Joseph P. Guglielmo
Scott+Scott Attorneys at Law LLP
About Sparrow
Sparrow tracks active class action settlements and provides summaries of publicly available information, including eligibility requirements, claim deadlines and links to official settlement materials.
(WorldFrontNews Editorial):- Sheridan, Wyoming Aug 27, 2026 (Issuewire.com) – A proposed $44 million class action settlement has been reached in In re Chantix (Varenicline) Marketing, Sales Practices & Products Liability Litigation (No. II), Case Nos. 22-MD-3050 (KPF) and 22-MC-3050, pending in the United States District Court for the Southern District of New York. The settlement resolves claims concerning Pfizer Inc.’s manufacture and sale of the smoking-cessation drug Chantix.
According to the court-approved settlement notice, plaintiffs alleged that Pfizer failed to comply with current Good Manufacturing Practices, which they claimed resulted in Chantix becoming contaminated with a nitrosamine. Plaintiffs also alleged that Pfizer misrepresented its adherence to current Good Manufacturing Practices in connection with the manufacture of Chantix.
The litigation asserted claims including violations of state consumer-protection laws, unjust enrichment, negligent misrepresentation and other theories. The court previously limited the claims that could proceed, including certain claims based on allegations concerning Pfizer’s representations about its manufacturing practices. Pfizer denies wrongdoing and denies violating any law. The court has not decided which side is correct.
The parties agreed to settle the case rather than continue through litigation and trial. According to the settlement notice, the agreement allows both sides to avoid the uncertainties and expenses associated with continued litigation while providing compensation to qualifying settlement class members if the settlement receives final approval.
Who May Be Eligible
The Settlement Class generally includes individual consumers and third-party payors who paid any amount of money for retail purchases of Chantix in the United States or its territories from September 29, 2015 through September 17, 2021.
Certain parties are excluded, including Pfizer and specified affiliated individuals and entities, government agencies or governmental actors, and parties that previously excluded themselves from the applicable class.
Settlement Benefits
Pfizer has agreed to establish a $44 million Settlement Fund. Payments to settlement class members, settlement administration and notice expenses, court-approved attorneys’ fees and litigation expenses, and any approved service awards will be paid from the fund.
For individual consumers, up to 20% of the Available Settlement Fund will be allocated to approved consumer claims. Each qualifying consumer’s payment will be calculated on a pro rata basis according to the amount the consumer paid for Chantix, and no consumer payment will exceed the amount that individual paid for the drug.
After the consumer allocation, the remaining funds will generally be distributed to qualifying third-party payors on a pro rata basis according to their qualifying and documented payments.
Because payments depend on the number and value of valid claims submitted, the settlement does not provide a fixed individual payout amount.
Documentation Requirements for Consumers
Individual consumers are not required to submit purchase documentation with their initial claim. However, the Settlement Administrator may later request supporting proof.
Examples of acceptable documentation include:
- An insurance explanation of benefits showing payment for Chantix
- Pharmacy records showing purchases of Chantix
- Records showing prescriptions written for Chantix
Consumers must report the number of Chantix prescriptions they purchased and the amount they paid out of pocket, and must certify that the information provided is accurate. Claims may be audited, and the Settlement Administrator may request additional documentation.
Claim Deadline
The deadline to submit a claim is September 14, 2026. Online claims must be submitted by the applicable deadline, while mailed claim forms must be postmarked no later than September 14, 2026.
The deadline to request exclusion from the settlement or object to the proposed settlement is also September 14, 2026.
The Court has scheduled a Final Approval Hearing for October 13, 2026 at 3:00 p.m. before U.S. District Judge Katherine Polk Failla in the Southern District of New York. The hearing date may change, and settlement class members should review the official settlement materials for updates.
Sparrow, a platform that tracks class action and settlement deadlines, has published information about the Chantix settlement to help consumers review publicly available details concerning eligibility, filing deadlines and settlement benefits. Sparrow is not the Settlement Administrator, Class Counsel or legal counsel in this matter. Individuals should rely on the official settlement website and court-approved documents for complete terms and instructions.
The Settlement Administrator for the matter is A.B. Data, Ltd. Settlement inquiries may be directed to:
Chantix Settlement
c/o A.B. Data, Ltd.
P.O. Box 173137
Milwaukee, WI 53217
Phone: 1-877-354-3912
Court-appointed Class Counsel includes:
Ruben Honik and David J. Stanoch
Honik LLC
Charles E. Schaffer
Levin Sedran & Berman LLP
Joseph P. Guglielmo
Scott+Scott Attorneys at Law LLP
About Sparrow
Sparrow tracks active class action settlements and provides summaries of publicly available information, including eligibility requirements, claim deadlines and links to official settlement materials.
This article was originally published by IssueWire. Read the original article here.
